IT202200009101A1 - ANTIOXIDANT COMPOSITION TO PREVENT AND TREAT INFLAMMATORY STATES OF THE RESPIRATORY TRACTS PARTICULARLY OF THE LUNG - Google Patents

ANTIOXIDANT COMPOSITION TO PREVENT AND TREAT INFLAMMATORY STATES OF THE RESPIRATORY TRACTS PARTICULARLY OF THE LUNG Download PDF

Info

Publication number
IT202200009101A1
IT202200009101A1 IT102022000009101A IT202200009101A IT202200009101A1 IT 202200009101 A1 IT202200009101 A1 IT 202200009101A1 IT 102022000009101 A IT102022000009101 A IT 102022000009101A IT 202200009101 A IT202200009101 A IT 202200009101A IT 202200009101 A1 IT202200009101 A1 IT 202200009101A1
Authority
IT
Italy
Prior art keywords
lung
prevent
antioxidant composition
treat inflammatory
respiratory tracts
Prior art date
Application number
IT102022000009101A
Other languages
Italian (it)
Inventor
Michele Pironti
Original Assignee
Aqma Italia S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aqma Italia S P A filed Critical Aqma Italia S P A
Priority to IT102022000009101A priority Critical patent/IT202200009101A1/en
Publication of IT202200009101A1 publication Critical patent/IT202200009101A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
IT102022000009101A 2022-05-04 2022-05-04 ANTIOXIDANT COMPOSITION TO PREVENT AND TREAT INFLAMMATORY STATES OF THE RESPIRATORY TRACTS PARTICULARLY OF THE LUNG IT202200009101A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IT102022000009101A IT202200009101A1 (en) 2022-05-04 2022-05-04 ANTIOXIDANT COMPOSITION TO PREVENT AND TREAT INFLAMMATORY STATES OF THE RESPIRATORY TRACTS PARTICULARLY OF THE LUNG

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102022000009101A IT202200009101A1 (en) 2022-05-04 2022-05-04 ANTIOXIDANT COMPOSITION TO PREVENT AND TREAT INFLAMMATORY STATES OF THE RESPIRATORY TRACTS PARTICULARLY OF THE LUNG

Publications (1)

Publication Number Publication Date
IT202200009101A1 true IT202200009101A1 (en) 2023-11-04

Family

ID=83188803

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102022000009101A IT202200009101A1 (en) 2022-05-04 2022-05-04 ANTIOXIDANT COMPOSITION TO PREVENT AND TREAT INFLAMMATORY STATES OF THE RESPIRATORY TRACTS PARTICULARLY OF THE LUNG

Country Status (1)

Country Link
IT (1) IT202200009101A1 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013067284A1 (en) * 2011-11-04 2013-05-10 The Leland Stanford Junior University Methods of improving or preserving lung function in a patient with a pulmonary disorder
US20130273175A1 (en) * 2012-04-15 2013-10-17 Jahahreeh Finley Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
WO2016210226A1 (en) * 2015-06-26 2016-12-29 Stc.Unm Coenzyme q10 aerosol
WO2018017434A1 (en) * 2016-07-16 2018-01-25 Burch Lauranell Harrison Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
WO2020081886A1 (en) * 2018-10-18 2020-04-23 The Regents Of The University Of California Homotaurine for treatment of inflammation-related disorders
WO2021216749A1 (en) * 2020-04-22 2021-10-28 George Edward Hoag Method for treating viral and bacterial infection through inhalation therapy
US20210369741A1 (en) * 2020-05-27 2021-12-02 Northwestern University Vitamin d as an immune modulator to prevent immune-related complication from covid-19 infection
WO2022011305A2 (en) * 2020-07-09 2022-01-13 Beyond Barriers Therapeutics, Inc. Intranasal administration of an antioxidant compound for treating coronavirus infection

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013067284A1 (en) * 2011-11-04 2013-05-10 The Leland Stanford Junior University Methods of improving or preserving lung function in a patient with a pulmonary disorder
US20130273175A1 (en) * 2012-04-15 2013-10-17 Jahahreeh Finley Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
WO2016210226A1 (en) * 2015-06-26 2016-12-29 Stc.Unm Coenzyme q10 aerosol
WO2018017434A1 (en) * 2016-07-16 2018-01-25 Burch Lauranell Harrison Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
WO2020081886A1 (en) * 2018-10-18 2020-04-23 The Regents Of The University Of California Homotaurine for treatment of inflammation-related disorders
WO2021216749A1 (en) * 2020-04-22 2021-10-28 George Edward Hoag Method for treating viral and bacterial infection through inhalation therapy
US20210369741A1 (en) * 2020-05-27 2021-12-02 Northwestern University Vitamin d as an immune modulator to prevent immune-related complication from covid-19 infection
WO2022011305A2 (en) * 2020-07-09 2022-01-13 Beyond Barriers Therapeutics, Inc. Intranasal administration of an antioxidant compound for treating coronavirus infection

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ABDULLAH CETIN TANRIKULU ET AL: "Coenzyme Q10, Copper, Zinc, and Lipid Peroxidation Levels in Serum of Patients with Chronic Obstructive Pulmonary Disease", BIOLOGICAL TRACE ELEMENT RESEARCH, HUMANA PRESS INC, NEW YORK, vol. 143, no. 2, 16 November 2010 (2010-11-16), pages 659 - 667, XP019961015, ISSN: 1559-0720, DOI: 10.1007/S12011-010-8897-5 *
CAZZOLA MARIO ET AL: "Use of Thiols in the Treatment of COVID-19: Current Evidence", LUNG, SPRINGER NEW YORK LLC, US, vol. 199, no. 4, 1 August 2021 (2021-08-01), pages 335 - 343, XP037555045, ISSN: 0341-2040, [retrieved on 20210827], DOI: 10.1007/S00408-021-00465-3 *
GUPTA R C ET AL: "TAURINE ANALOGUES; A NEW CLASS OF THERAPEUTICS: RETROSPECT AND PROSPECTS", CURRENT MEDICINAL CHEMISTRY, BENTHAM, NL, vol. 12, no. 17, 1 January 2005 (2005-01-01), pages 2021 - 2039, XP009082995, ISSN: 0929-8673, DOI: 10.2174/0929867054546582 *
I. RAHMAN ET AL: "Oxidative stress and regulation of glutathione in lung inflammation", EUROPEAN RESPIRATORY JOURNAL, vol. 16, no. 3, 1 September 2000 (2000-09-01), pages 534 - 554, XP055036719, ISSN: 0903-1936, DOI: 10.1034/j.1399-3003.2000.016003534.x *
SAHEBNASAGH ADELEH ET AL: "The prophylaxis and treatment potential of supplements for COVID-19", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 887, 1 September 2020 (2020-09-01), XP086323297, ISSN: 0014-2999, [retrieved on 20200901], DOI: 10.1016/J.EJPHAR.2020.173530 *
SIFUENTES-FRANCO SONIA ET AL: "Antioxidant and Anti-Inflammatory Effects of Coenzyme Q10 Supplementation on Infectious Diseases", HEALTHCARE, vol. 10, no. 3, 1 January 2022 (2022-01-01), pages 487, XP093009132, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953254/pdf/healthcare-10-00487.pdf> DOI: 10.3390/healthcare10030487 *
TALLARIDA RJ.: "Drug Synergism:its detection and applications.", J PHARMACOL EXPTHER, vol. 298, no. 3, September 2001 (2001-09-01), pages 865 - 72, XP007918154
TIAN JIDE ET AL: "GABAA-Receptor Agonists Limit Pneumonitis and Death in Murine Coronavirus-Infected Mice", VIRUSES, vol. 13, no. 6, 23 May 2021 (2021-05-23), pages 966, XP093009129, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224554/pdf/viruses-13-00966.pdf> DOI: 10.3390/v13060966 *
ZHANG QIANWEN ET AL: "N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia : A randomized controlled trial", MEDICINE, vol. 97, no. 45, 1 November 2018 (2018-11-01), US, pages e13087, XP093009131, ISSN: 0025-7974, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250560/pdf/medi-97-e13087.pdf> DOI: 10.1097/MD.0000000000013087 *

Similar Documents

Publication Publication Date Title
MX2008009725A (en) Sterilized nanoparticulate glucocorticosteroid formulations.
CY1123367T1 (en) METHODS AND COMPOSITIONS FOR REGULATING THE EXPRESSION OF APOLYPOPROTEIN (A)
PE20081788A1 (en) PHARMACEUTICAL COMBINATIONS
MX2019003397A (en) Methods of treating mitochondrial and metabolic disorders.
HRP20121034T1 (en) Treatment of inflammatory diseases
PE20141532A1 (en) NEW PIPERIDINE-DIHYDROTIENOPYRIMIDINE SULFOXIDES AND THEIR USE TO TREAT COPD AND ASTHMA
CY1120802T1 (en) composition
HK1137807A1 (en) Diagnosis of infections or inflammatory diseases of the airways and lungs associated with heart failure
BR112016006064A2 (en) pro-dentifrice composition, glycerin based composition, and oral mucosa therapy kit
BR112014032801A2 (en) racecadotril liquid compositions
SMAP201000048A (en) Use of streptococcus salivarius in the treatment of chronic respiratory infections
MX363035B (en) Use of a composition comprising fish oil and juice for the treatment of inflammation.
BR112014030534A2 (en) galacto-ramnogalacturonate compositions for the treatment of diseases associated with high inducible nitric oxide synthase
SMT201700098B (en) ACLIDINUM FOR USE IN IMPROVING THE QUALITY OF SLEEP IN PATIENTS WITH RESPIRATORY DISEASES
BR112015001859A2 (en) inflammation treatment using serelaxine
IT1404171B1 (en) COMPOSITION FOR USE IN THE TREATMENT OF PROBLEMS / DISORDERS OF THE MENOPAUSE AND IN THE TREATMENT OF THE GENERAL AGING OF THE ORGANISM
IT202200009101A1 (en) ANTIOXIDANT COMPOSITION TO PREVENT AND TREAT INFLAMMATORY STATES OF THE RESPIRATORY TRACTS PARTICULARLY OF THE LUNG
BR112013018688A2 (en) process for the production of proanthocyanidin polymer composition
BR112014004737A2 (en) Ambroxol Hydrochloride Compound Compound and Method of Preparation of Compound
IL297304A (en) Composition for the treatment of respiratory symptoms and methods thereof
MX2015013409A (en) Silybin for the treatment of metabolic oxidative alterations in patients with non-alcoholic steatohepatitis (nash).
ITMI20080172A1 (en) ORAL FORMULATIONS FOR PROTECTION OF RESPIRATORY PATHWAYS WITH SPECIAL REFERENCE TO INFLAMMATORY AND NEOPLASTIC PHENOMENA
ZA200800251B (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
TW200738247A (en) Method and composition for treating allergic diseases
BR112013026004A2 (en) human gdnf variants